Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics

Advanced Drug Delivery Reviews

Volumn 61, Issue 11, 2009, Pages 977-985

  Nagata, Satoshi ^a   Pastan, Ira ^b  

^a SANFORD RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody; Antigen; Antigenicity; Biopharmaceutical; Deimmunization; Mutagenesis

Indexed keywords

ANTIGENICITY; B CELLS; BACTERIAL PROTEIN; BIOPHARMACEUTICAL; DEIMMUNIZATION; EXPERIMENTAL DATA; EXPERIMENTAL EVIDENCE; FUNCTIONAL PROTEINS; HUMAN PROTEINS; IMMUNOGENICITY; IMMUNOTOXINS; PROTEIN THERAPEUTICS; PSEUDOMONAS EXOTOXIN A; QUANTITATIVE ANALYSIS; THEORETICAL ASPECTS; THERAPEUTIC PROPERTIES;

ANTIBODIES; ANTIGENS; LIGANDS; MUTAGENESIS; POLYPEPTIDES;

CELL MEMBRANES;

ANTIBODY; ANTIGEN; CD22 ANTIGEN; CONFORMATIONAL EPITOPE; EPITOPE; INTERLEUKIN 2 RECEPTOR ALPHA; LINEAR EPITOPE; NEUTRALIZING ANTIBODY; PSEUDOMONAS EXOTOXIN; PSEUDOMONAS EXOTOXIN A; UNCLASSIFIED DRUG;

ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; B LYMPHOCYTE; CANCER RESISTANCE; CD25+ T LYMPHOCYTE; DEIMMUNIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HAIRY CELL LEUKEMIA; HUMAN; IMMUNE COMPLEX CAPTURE ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; INTERMETHOD COMPARISON; MUTAGENESIS; NEOPLASM; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; REMISSION; REVIEW;

ANIMALS; ANTIBODY AFFINITY; ANTIGEN-ANTIBODY REACTIONS; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; HUMANS; IMMUNOTOXINS; MUTAGENESIS; POINT MUTATION; PROTEIN CONFORMATION; PROTEINS;

EID: 70349453934     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.07.014     Document Type: Review

References (100)

1. Leader B., Baca Q.J., and Golan D.E. Protein therapeutics: a summary and pharmacological classification. Nat. Rev. Drug Discov. 7 (2008) 21-39
2. Johnson-Leger C., Power C.A., Shomade G., Shaw J.P., and El Proudfoot A. Protein therapeutics - lessons learned and a view of the future. Expert Opin. Biol. Th. 6 (2006) 1-7
3. Crommelin D.J., Storm G., Verrijk R., de Leede L., Jiskoot W., and Hennink W.E. Shifting paradigms: biopharmaceuticals versus low molecular weight drugs. Int. J. Pharm. 266 (2003) 3-16
4. Subramanyam M. Immunogenicity of biotherapeutics-an overview. J. Immunotoxicol. 3 (2006) 151-156
5. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24 (2002) 1720-1740
6. Khan I.A., and Gowda R.M. Clinical perspectives and therapeutics of thrombolysis. Int. J. Cardiol. 91 (2003) 115-127
7. Mahajan S.T., and Brubaker L. Botulinum toxin: from life-threatening disease to novel medical therapy. Am. J. Obstet. Gynecol. 196 (2007) 7-15
8. Yablon S.A., Brashear A., Gordon M.F., Elovic E.P., Turkel C.C., Daggett S., Liu J.Y., and Brin M.F. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin. Ther. 29 (2007) 683-690
9. Shankar G., Pendley C., and Stein K.E. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol. 25 (2007) 555-561
10. Pastan I., Hassan R., FitzGerald D.J., and Kreitman R.J. Immunotoxin treatment of cancer. Annu. Rev. Med. 58 (2007) 221-237
11. Pastan I., Hassan R., Fitzgerald D.J., and Kreitman R.J. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6 (2006) 559-565
12. FitzGerald D.J., Kreitman R., Wilson W., Squires D., and Pastan I. Recombinant immunotoxins for treating cancer. Int. J. Med. Microbiol. 293 (2004) 577-582
13. Kreitman R.J., Squires D.R., Stetler-Stevenson M., Noel P., FitzGerald D.J., Wilson W.H., and Pastan I. Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J. Clin. Oncol. 23 (2005) 6719-6729
14. Kreitman R.J., Wilson W.H., Bergeron K., Raggio M., Stetler-Stevenson M., FitzGerald D.J., and Pastan I. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345 (2001) 241-247
15. Laroche Y., Heymans S., Capaert S., De Cock F., Demarsin E., and Collen D. Recombinant staphylokinase variants with reduced antigenicity due to elimination of B-lymphocyte epitopes. Blood 96 (2000) 1425-1432
16. Mayer A., Sharma S.K., Tolner B., Minton N.P., Purdy D., Amlot P., Tharakan G., Begent R.H., and Chester K.A. Modifying an immunogenic epitope on a therapeutic protein: a step towards an improved system for antibody-directed enzyme prodrug therapy (ADEPT). Br. J. Cancer 90 (2004) 2402-2410
17. Onda M., Nagata S., FitzGerald D.J., Beers R., Fisher R.J., Vincent J.J., Lee B., Nakamura M., Hwang J., Kreitman R.J., Hassan R., and Pastan I. Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients. J. Immunol. 177 (2006) 8822-8834
18. Onda M., Beers R., Xiang L., Nagata S., Wang Q.C., and Pastan I. An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 11311-11316
19. Eisen H.N., and Siskind G.W. Variations in affinities of antibodies during the immune response. Biochemistry 3 (1964) 996-1008
20. Tai Kim Y., Greenbaum D., Davis P., Fink S.A., Werblin T.P., and Siskind G.W. Studies on the control of antibody synthesis. IX. Effect of boosting on antibody affinity. J. Immunol. 114 (1975) 1302-1306
21. Marzocchi-Machado C.M., Polizello A.C., Azzolini A.E., and Lucisano-Valim Y.M. The influence of antibody functional affinity on the effector functions involved in the clearance of circulating immune complexes anti-BSA IgG/BSA. Immunol. Invest. 28 (1999) 89-101
22. Kawade Y., Finter N., and Grossberg S.E. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J. Immunol. Methods 278 (2003) 127-144
23. Alpers J.H., Steward M.W., and Soothill J.F. Differences in immune elimination in inbred mice. The role of low affinity antibody. Clin. Exp. Immunol. 12 (1972) 121-132
24. Liang M., Klakamp S.L., Funelas C., Lu H., Lam B., Herl C., Umble A., Drake A.W., Pak M., Ageyeva N., Pasumarthi R., and Roskos L.K. Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms. Assay Drug Dev. Technol. 5 (2007) 655-662
25. Shankar G., Devanarayan V., Amaravadi L., Barrett Y.C., Bowsher R., Finco-Kent D., Fiscella M., Gorovits B., Kirschner S., Moxness M., Parish T., Quarmby V., Smith H., Smith W., Zuckerman L.A., and Koren E. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J. Pharm. Biomed. Anal. 48 (2008) 1267-1281
26. MacLennan I.C. Germinal centers. Annu. Rev. Immunol. 12 (1994) 117-139
27. Parker D.C. T cell-dependent B cell activation. Annu. Rev. Immunol. 11 (1993) 331-360
28. Bernard A., Coitot S., Bremont A., and Bernard G. T and B cell cooperation: a dance of life and death. Transplantation 79 (2005) S8-S11
29. Abbas A.K. Antigen presentation by B lymphocytes: mechanisms and functional significance. Semin. Immunol. 1 (1989) 5-12
30. Pieters J. MHC class II-restricted antigen processing and presentation. Adv. Immunol. 75 (2000) 159-208
31. Kawabe T., Naka T., Yoshida K., Tanaka T., Fujiwara H., Suematsu S., Yoshida N., Kishimoto T., and Kikutani H. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1 (1994) 167-178
32. Renshaw B.R., Fanslow W.C., Armitage R.J., Campbell K.A., Liggitt D., Wright B., Davison B.L., and Maliszewski C.R. Humoral immune-responses in CD40 ligand-deficient mice. J. Exp. Med. 180 (1994) 1889-1900
33. Brons N.H., Blaich A., Wiesmuller K.H., Schneider F., Jung G., and Muller C.P. Hierarchic T-cell help to non-linked B-cell epitopes. Scand. J. Immunol. 44 (1996) 478-484
34. Rosenberg J.S., and Atassi M.Z. Intersite helper function of T cells specific for a protein epitope that is not recognized by antibodies. Immunol. Invest. 26 (1997) 473-489
35. Mukovozov I., Sabljic T., Hortelano G., and Ofosu F.A. Factors that contribute to the immmunogenicity of therapeutic recombinant human proteins. Thromb. Haemost. 99 (2008) 874-882
36. Boulianne G.L., Hozumi N., and Shulman M.J. Production of functional chimaeric mouse/human antibody. Nature 312 (1984) 643-646
37. Morrison S.L., Johnson M.J., Herzenberg L.A., and Oi V.T. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. U. S. A. 81 (1984) 6851-6855
38. Jones P.T., Dear P.H., Foote J., Neuberger M.S., and Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature 321 (1986) 522-525
39. Kanduc D. Immunogenicity in peptide-immunotherapy: from self/nonself to similar/dissimilar sequences. Adv. Exp. Med. Biol. 640 (2008) 198-207
40. Shankar G., Shores E., Wagner C., and Mire-Sluis A. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 24 (2006) 274-280
41. van den Berg H.A., and Rand D.A. Foreignness as a matter of degree: the relative immunogenicity of peptide/MHC ligands. J. Theor. Biol. 231 (2004) 535-548
42. Paul W.E. Fundamental Immunology (2003), Lippincott Williams & Wilkins, Philadelphia
43. Goodnow C.C. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 2264-2271
44. Ferry H., Leung J.C., Lewis G., Nijnik A., Silver K., Lambe T., and Cornall R.J. B-cell tolerance. Transplantation 81 (2006) 308-315
45. Bugelski P.J., and Treacy G. Predictive power of preclinical studies of recombinant therapeutic proteins in animals for the immunogenicity humans. Curr. Opin. Mol. Ther. 6 (2004) 10-16
46. Vanderschueren S.M., Stassen J.M., and Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb. Haemost. 72 (1994) 297-301
47. McCabe W.R., DeMaria A., and Johns M. Potential use of shared antigens for immunization against gram-negative bacillary infections. Prog. Clin. Biol. Res. 47 (1980) 107-117
48. S. Wallach, The role of calcitonin treatment in postmenopausal osteoporosis, Orthop. Rev. 21 (1992) 1034-1042, 1130-1031
49. Wang Z.G., Williams L.J., Zhang X.F., Zatorski A., Kudryashov V., Ragupathi G., Spassova M., Bornmann W., Slovin S.F., Scher H.I., Livingston P.O., Lloyd K.O., and Danishefsky S.J. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 2719-2724
50. Dolimbek B.Z., Aoki K.R., Steward L.E., Jankovic J., and Atassi M.Z. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol. Immunol. 44 (2007) 1029-1041
51. Atassi M.Z., and Dolimbek B.Z. Mapping of the antibody-binding regions on the H-N-domain (residues 449-859) of botulinum neurotoxin A with antitoxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J. 23 (2004) 39-52
52. Korber B.T.M., Brander C., Haynes B.F., Koup R., Moore J.P., Walker B.D., and Watkins D.I. HIV Molecular Immunology 2006/2007, Los Alamos, NM: Theoretical Biology and Biophysics Group (2007), Los Alamos National Laboratory
53. Van Regenmortel M.H. Antigenicity and immunogenicity of synthetic peptides. Biologicals 29 (2001) 209-213
54. Selvarajah S., Puffer B., Pantophlet R., Law M., Doms R.W., and Burton D.R. Comparing antigenicity and immunogenicity of engineered gp120. J. Virol. 79 (2005) 12148-12163
55. Berzofsky J.A. Intrinsic and extrinsic factors in protein antigenic structure. Science 229 (1985) 932-940
56. Van Regenmortel M.H. Reductionism and the search for structure-function relationships in antibody molecules. J. Mol. Recognit. 15 (2002) 240-247
57. Geysen H.M., Tainer J.A., Rodda S.J., Mason T.J., Alexander H., Getzoff E.D., and Lerner R.A. Chemistry of antibody binding to a protein. Science 235 (1987) 1184-1190
58. Van Regenmortel M.H. What is a B-cell epitope?. Methods Mol. Biol. 524 (2009) 3-20
59. Davies D.R., Padlan E.A., and Sheriff S. Antibody-antigen complexes. Annu. Rev. Biochem. 59 (1990) 439-473
60. van Regenmortel M.H.V. Structure of Antigens Volume I (1992), CRC Press, Florida
61. van Regenmortel M.H.V. Structure of Antigens Volume II (1992), CRC Press, Florida
62. Padlan E.A. Antibody-Antigen Complex (1994), CRC Press, Florida
63. Almagro J.C. Identification of differences in the specificity-determining residues of antibodies that recognize antigens of different size: implications for the rational design of antibody repertoires. J. Mol. Recognit. 17 (2004) 132-143
64. Schlessinger A., Ofran Y., Yachdav G., and Rost B. Epitome: database of structure-inferred antigenic epitopes. Nucleic Acids Res. 34 (2006) D777-D780
65. Westhof E., Altschuh D., Moras D., Bloomer A.C., Mondragon A., Klug A., and Van Regenmortel M.H. Correlation between segmental mobility and the location of antigenic determinants in proteins. Nature 311 (1984) 123-126
66. Blythe M.J., and Flower D.R. Benchmarking B cell epitope prediction: underperformance of existing methods. Protein Sci. 14 (2005) 246-248
67. Greenbaum J.A., Andersen P.H., Blythe M., Bui H.H., Cachau R.E., Crowe J., Davies M., Kolaskar A.S., Lund O., Morrison S., Mumey B., Ofran Y., Pellequer J.L., Pinilla C., Ponomarenko J.V., Raghava G.P., van Regenmortel M.H., Roggen E.L., Sette A., Schlessinger A., Sollner J., Zand M., and Peters B. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J. Mol. Recognit. 20 (2007) 75-82
68. Pellequer J.L., Westhof E., and Van Regenmortel M.H. Predicting location of continuous epitopes in proteins from their primary structures. Methods Enzymol. 203 (1991) 176-201
69. Chen J., Liu H., Yang J., and Chou K. Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino Acids 33 (2007) 423-428
70. Haste Andersen P., Nielsen M., and Lund O. Prediction of residues in discontinuous B-cell epitopes using protein 3D structures. Protein Sci. 15 (2006) 2558-2567
71. Reimer U. Prediction of linear B-cell epitopes. Methods Mol. Biol. 524 (2009) 335-344
72. Rubinstein N.D., Mayrose I., and Pupko T. A machine-learning approach for predicting B-cell epitopes. Mol. Immunol. 46 (2009) 840-847
73. Ponomarenko J., Bui H.H., Li W., Fusseder N., Bourne P.E., Sette A., and Peters B. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 9 (2008) 8
74. Peters B., and Sette A. Integrating epitope data into the emerging web of biomedical knowledge resources. Nat. Rev. Immunol. 7 (2007) 485-490
75. Peters B., Sidney J., Bourne P., Bui H.H., Buus S., Doh G., Fleri W., Kronenberg M., Kubo R., Lund O., Nemazee D., Ponomarenko J.V., Sathiamurthy M., Schoenberger S.P., Stewart S., Surko P., Way S., Wilson S., and Sette A. The design and implementation of the immune epitope database and analysis resource. Immunogenetics 57 (2005) 326-336
76. Barlow D.J., Edwards M.S., and Thornton J.M. Continuous and discontinuous protein antigenic determinants. Nature. 322 (1986) 747-748
77. Laver W.G., Air G.M., Webster R.G., and Smithgill S.J. Epitopes on protein antigens - misconceptions and realities. Cell 61 (1990) 553-556
78. Harlow E., and Lane P. Epitope Mapping, Using Antibodies: a Laboratory Manual (1999), Cold Spring Harbor Laboratory Press, NY 381-405
79. Carter J.M., and Loomis-Price L. B cell epitope mapping using synthetic peptides. Chapter. Curr. Protoc. Immunol. 9 (2004) Unit 9 4
80. Fack F., Hugle-Dorr B., Song D., Queitsch I., Petersen G., and Bautz E.K. Epitope mapping by phage display: random versus gene-fragment libraries. J. Immunol. Methods 206 (1997) 43-52
81. Vijayendran R.A., and Leckband D.E. A quantitative assessment of heterogeneity for surface-immobilized proteins. Anal. Chem. 73 (2001) 471-480
82. Schwab C., and Bosshard H.R. Caveats for the use of surface-adsorbed protein antigen to test the specificity of antibodies. J. Immunol. Methods 147 (1992) 125-134
83. Butler J.E., Ni L., Nessler R., Joshi K.S., Suter M., Rosenberg B., Chang J., Brown W.R., and Cantarero L.A. The physical and functional behavior of capture antibodies adsorbed on polystyrene. J. Immunol. Methods 150 (1992) 77-90
84. Rabbany S.Y., Piervincenzi R., Judd L., Kusterbeck A.W., Bredehorst R., Hakansson K., and Ligler F.S. Assessment of heterogeneity in antibody-antigen displacement reactions. Anal. Chem. 69 (1997) 175-182
85. Jin L., and Wells J.A. Mutational analysis of antibody binding sites. In: Van Regenmortel M. (Ed). Structure of Antigens Vol. 3 (1995), CRC Press, Boca Raton 21-36
86. Mitchell A.J., Edwards M.R., and Collins A.M. Valency or wahlency: is the epitope diversity of the B-cell response regulated or chemically determined?. Immunol. Cell Biol. 79 (2001) 507-511
87. Mueller C.M., Minnerath J.M., and Jemmerson R. B lymphocyte recognition of the self antigen mouse cytochrome C in different mouse strains: targeting of the same dominant epitope by naturally-occurring cells expressing distinct VH genes. Mol. Immunol. 34 (1997) 843-853
88. Tzartos S.J. Epitope mapping by antibody competition. Methodology and evaluation of the validity of the technique. Methods Mol. Biol. 66 (1996) 55-66
89. Kuroki M., Wakisaka M., Murakami M., Haruno M., Arakawa F., Higuchi H., and Matsuoka Y. Determination of epitope specificities of a large number of monoclonal antibodies by solid-phase mutual inhibition assays using biotinylated antigen. Immunol. Invest. 21 (1992) 523-538
90. Nagata S., Numata Y., Onda M., Ise T., Hahn Y., Lee B., and Pastan I. Rapid grouping of monoclonal antibodies based on their topographical epitopes by a label-free competitive immunoassay. J. Immunol. Methods 292 (2004) 141-155
91. Jemmerson R. Multiple overlapping epitopes in the three antigenic regions of horse cytochrome c1. J. Immunol. 138 (1987) 213-219
92. Newman M.A., Mainhart C.R., Mallett C.P., Lavoie T.B., and Smith-Gill S.J. Patterns of antibody specificity during the BALB/c immune response to hen eggwhite lysozyme. J. Immunol. 149 (1992) 3260-3272
93. Jin L., Fendly B.M., and Wells J.A. High resolution functional analysis of antibody-antigen interactions. J. Mol. Biol. 226 (1992) 851-865
94. Jin L., and Wells J.A. Dissecting the energetics of an antibody-antigen interface by alanine shaving and molecular grafting. Protein Sci. 3 (1994) 2351-2357
95. Cunningham B.C., and Wells J.A. High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis. Science. 244 (1989) 1081-1085
96. Meyer D.L., Schultz J., Lin Y.K., Henry A., Sanderson J., Jackson J.M., Goshorn S., Rees A.R., and Graves S.S. Reduced antibody response to streptavidin through site-directed mutagenesis. Protein Sci. 10 (2001) 491-503
97. Lee B., and Richards F.M. The interpretation of protein structures: estimation of static accessibility. J. Mol. Biol. 55 (1971) 379-400
98. Collen D., Bernaerts R., Declerck P., De Cock F., Demarsin E., Jenne S., Laroche Y., Lijnen H.R., Silence K., and Verstreken M. Recombinant staphylokinase variants with altered immunoreactivity. I: construction and characterization. Circulation 94 (1996) 197-206
99. Nagata S., Ise T., Onda M., Nakamura K., Ho M., Raubitschek A., and Pastan I. Cell membrane-specific epitopes on CD30: potentially superior targets for immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 7946-7951 Erratum, ibid 103 (2006) 3007
100. Du X., Nagata S., Ise T., Stetler-Stevenson M., and Pastan I. FCRL1 on chronic lymphocytic leukemia, hairy cell leukemia, and B-cell non-Hodgkin lymphoma as a target of immunotoxins. Blood 111 (2008) 338-343